NV9.F · Kazia Therapeutics Limited

-

Please sign in to comment on NV9.F

1 Comment

Admin

4 years, 1 month ago

Kazia Therapeutics Limited is currently in a long term uptrend where the price is trading 6.9% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Kazia Therapeutics Limited's total revenue sank by 0.0% to $313K since the same quarter in the previous year.

Its net income has dropped by 0.0% to $-3M since the same quarter in the previous year.

Finally, its free cash flow fell by 348.4% to $-6M since the same quarter in the previous year.

Based on the above factors, Kazia Therapeutics Limited gets an overall score of 2/5.

ISIN	None
Sector
Industry
Exchange	F
CurrencyCode	EUR

Beta	1.98
PE Ratio	None
Target Price	None
Dividend Yield	0.0%
Market Cap	102M

ABOUT

Kazia Therapeutics Limited

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

NV9.F · Kazia Therapeutics Limited

-

Kazia Therapeutics Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Kazia Therapeutics Limited using a moving average strategy